Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial

Autor: D. Zips, D.G. Bosetti, M. Pinkawa, Marcin Sumila, V. Budach, Davide G. Bosetti, P.M. Putora, G. Pesce, George N. Thalmann, Daniel M. Aebersold, Kaouthar Khanfir, Jürg Bernhard, Bülent Polat, F. Zimmermann, S. Gomez, Piet Ost, K. Berkovic, F. Behrensmeier, P. Wust, L. Plasswilm, J. Collon, P. Messer, S. Bodis, M. Baumann, Silvia Gomez, M. Sumila, V. Lewitzki, M. Sassowsky, H. Kranzbühler, Kathrin Zaugg, Peter Wust, D.M. Aebersold, P. Thum, M. Guckenberger, Matthias Guckenberger, Y. Najafi, S. Wuttke, C. Belka, D.R. Zwahlen, Guido Hildebrandt, Pirus Ghadjar, A. Papachristofilou, Philipp Gut, Corinne Schär, G.N. Thalmann, F. Vandaele, K. Beer, P. Ost, M. Stuschke, M. Flentje, A. Müller, C. Reuter, P. Ghadjar, C. Oehler, Christiane Reuter, Daniel R. Zwahlen, I. Tacacs, Arndt-Christian Müller, M. Brown, K. Khanfir, G. Hildebrandt, Ludwig Plasswilm, T. Hölscher, N.C. Azinwi, Tobias Hölscher, M.J. Eble, U. Ganswindt, Stefanie Hayoz, P. Gut, Alexandros Papachristofilou, B. Polat, K. Zaugg
Rok vydání: 2021
Předmět:
Zdroj: European Urology. 80:306-315
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2021.05.033
Popis: Background Salvage radiotherapy (SRT) is utilized for biochemical progression of prostate cancer after radical prostatectomy (RP). Objective To report the outcomes of the SAKK 09/10 trial comparing conventional and dose-intensified SRT. Design, setting, and participants SAKK 09/10 was a randomized, multicenter, phase 3 trial that recruited men with biochemical progression after RP. Intervention Patients were randomly assigned to conventional-dose (64 Gy) or dose-intensified SRT (70 Gy) to the prostate bed without hormonal therapy. Outcome measurements and statistical analysis The primary endpoint was freedom from biochemical progression (FFBP). Secondary endpoints included clinical progression-free survival (PFS), time to hormonal treatment, overall survival (OS), acute and late toxicity (Common Terminology Criteria for Adverse Events v4.0), and quality of life (QoL). Results and limitations Between February 2011 and April 2014, 350 patients were randomly assigned to 64 Gy (n = 175) or 70 Gy (n = 175). Median prostate-specific antigen at randomization was 0.3 ng/ml. After median follow-up of 6.2 yr, the median FFBP was 8.2 yr in the 64 Gy arm and 7.6 in the 70 Gy arm (log-rank p = 0.4), with a hazard ratio of 1.14 (95% confidence interval 0.82–1.60). The 6-year FFBP rates were 62% and 61%, respectively. No significant differences in clinical PFS, time to hormonal treatment, or OS were observed. Late grade 2 and 3 genitourinary toxicity was observed in 35 (21%) and 13 (7.9%) patients in the 64 Gy arm, and 46 (26%) and seven (4%) in the 70 Gy arm, respectively (p = 0.8). Late grade 2 and 3 gastrointestinal toxicity was observed in 12 (7.3%) and seven patients (4.2%) in the 64 Gy arm, and 35 (20%) and four (2.3%) in the 70 Gy arm, respectively (p = 0.009). There were no significant differences in QoL. Conclusions Conventional-dose SRT to the prostate bed is sufficient in patients with early biochemical progression of prostate cancer after RP. Patient summary The optimal radiation therapy dose for patients who have increased tumor markers after surgery for prostate cancer is unclear. We found that administering a higher dose only increased the gastrointestinal side effects without providing any benefits to the patient. This clinical trial is registered on ClinicalTrials.gov as NCT01272050.
Databáze: OpenAIRE
Externí odkaz: